Long-term exposure to trihalomethanes in drinking water and breast cancer in the Spanish multicase-control study on cancer (MCC-SPAIN)
Por:
Font-Ribera L, Gràcia-Lavedan E, Aragonés N, Pérez-Gómez B, Pollán M, Amiano P, Jiménez-Zabala A, Castaño-Vinyals G, Roca-Barceló A, Ardanaz E, Burgui R, Molina AJ, Fernández-Villa T, Gómez-Acebo I, Dierssen-Sotos T, Moreno V, Fernandez-Tardon G, Peiró R, Kogevinas M and Villanueva CM
Publicada:
1 mar 2018
Categoría:
Environmental science (miscellaneous)
Resumen:
Background: Exposure to trihalomethanes (THMs) in drinking water has consistently been associated with an increased risk of bladder cancer, but evidence on other cancers including the breast is very limited.
Objectives: We assessed long-term exposure to THMs to evaluate the association with female breast cancer (BC) risk.
Methods: A multi case-control study was conducted in Spain from 2008 to 2013. We included 1003 incident BC cases (women 20-85 years old) recruited from 14 hospitals and 1458 population controls. Subjects were interviewed to ascertain residential histories and major recognized risk factors for BC. Mean residential levels of chloroform, brominated THMs (Br-THMs) and the sum of both as total THM (TTHMs) during the adult-lifetime were calculated.
Results: Mean adult-lifetime residential levels ranged from 0.8 to 145.7 mu g/L for TTHM (median= 30.8), from 0.2 to 62.4 mu g/L for chloroform (median = 19.7) and from 0.3 to 126.0 mu g/L for Br-THMs (median= 9.7). Adult-lifetime residential chloroform was associated with BC (adjusted OR = 1.47; 95% CI = 1.05, 2.06 for the highest (> 24 mu g/L) vs. lowest (< 8 mu g/L) quartile; p-trend = 0.024). No association was detected for residential Br-THMs (OR= 0.91; 95% CI = 0.68, 1.23 for> 31 mu g/L vs.< 6 mu g/L) or TTHMs (OR = 1.14; 95% CI = 0.83, 1.57 for> 48 mu g/L vs.< 22 mu g/L).
Conclusions: At common levels in Europe, long-term residential total THMs were not related to female breast cancer. A moderate association with chloroform was suggested at the highest exposure category. This large epidemiological study with extensive exposure assessment overcomes several limitations of previous studies but further studies are needed to confirm these results.
Filiaciones:
Font-Ribera L:
ISGlobal, Barcelona, Spain
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Gràcia-Lavedan E:
ISGlobal, Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Aragonés N:
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
Pérez-Gómez B:
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
Pollán M:
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta De Hierro, Madrid, Spain
Amiano P:
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
Jiménez-Zabala A:
Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
Castaño-Vinyals G:
ISGlobal, Barcelona, Spain
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Roca-Barceló A:
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
Ardanaz E:
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Instituto de Salud Pública y Laboral de Navarra, Pamplona, Spain
Burgui R:
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Instituto de Salud Pública y Laboral de Navarra, Pamplona, Spain
Molina AJ:
Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Universidad de León, Spain
Fernández-Villa T:
Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Universidad de León, Spain
Gómez-Acebo I:
Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
Dierssen-Sotos T:
Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
Moreno V:
Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Spain
Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Spain
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
Fernandez-Tardon G:
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
University of Oviedo, Asturias, Spain
:
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Centre for Research in Public Health, Valencia, Spain
Kogevinas M:
ISGlobal, Barcelona, Spain
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
Villanueva CM:
ISGlobal, Barcelona, Spain
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
|